Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocyte progenitor cells (474 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 46 | 0.91 |
| pathways Reactome | 3 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 6949
Sealed predictions
- SHC3 in dopamine neurons, braak-0.41 (p 0.276) → +0.44 (p 0.240)receipt 6957
- SHC3 in oligodendrocytes, braak+0.13 (p 0.733) → -0.35 (p 0.360)receipt 6956
Swarm cases
receipt 6957: SHC3 in dopamine neurons, braak
- power
- full sample +0.05 (p 0.847, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.16 (p 0.532, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.18, sign flips 4; without severely affected donors +0.05 (p 0.847, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SHC3 in dopamine neurons.
case closed: nothing better to follow up.
receipt 6956: SHC3 in oligodendrocytes, braak
- power
- full sample -0.03 (p 0.894, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.03 (p 0.908, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.16 (p 0.526, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.08, sign flips 5; without severely affected donors -0.03 (p 0.894, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SHC3 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts